Lb Pharmaceuticals (LBRX) Depreciation & Amortization (CF) (2025 - 2026)
Lb Pharmaceuticals' quarterly Depreciation & Amortization (CF) came in at $82000.0 in Q1 2026, up 3.8% year-on-year from $79000.0 in Q1 2025, and up 3.8% quarter-over-quarter from $79000.0 in Q1 2025.
Lb Pharmaceuticals has reported Depreciation & Amortization (CF) for 2 years, with the latest figure at $82000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 3.8% year-over-year to $82000.0; the trailing twelve-month figure through Mar 2026 stood at $161000.0 (changed N/A YoY), and the FY2025 full-year result was $321000.0, up 252.75% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $82000.0, up from $79000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $82000.0 in Q1 2026, with the low at $79000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Lb Pharmaceuticals | 789.92 Mn | 789.92 Mn | - | 82,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82,000.00 |
| Mar 31, 2026 | 82,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Mar 31, 2025 | 79,000.00 |